Back to search

Peptide record

TPDB24045

Pep27anal4 Antibacterial Anticancer Antifungal Toxicity standard
27 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB24045
Pep27anal4
Antibacterial Anticancer Antifungal Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
Peptipedia ACP740 _ACP240 AntiCP 2.0 CancerPPD 2.0 SATPdb dbACP iACP-DRLF dbAMP
standard
No
A 27-aa standard natural multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from Peptipedia, ACP740 _ACP240, AntiCP 2.0, and other sources, with an available 3D structural model.
Sequence
MWKEFHNVLSSGQLLADKRWARWYNRW
Physicochemical Analysis
C162H233N47O38S1
CIPT
W
3478.98
10.70
6
2
13
+3
-1.34
-0.926
61.48
Mammalian: 30 hour Yeast: >20 hour E.coli: >10 hour
23490
675.20
6
Residue Composition
number
2
A
3
R
2
N
1
D
0
C
1
E
1
Q
1
G
1
H
0
I
3
L
2
K
1
M
1
F
0
P
2
S
0
T
4
W
1
Y
1
V
Amino Acid Distribution
A: 2 R: 3 N: 2 D: 1 C: 0 E: 1 Q: 1 G: 1 H: 1 I: 0 L: 3 K: 2 M: 1 F: 1 P: 0 S: 2 T: 0 W: 4 Y: 1 V: 1
Chemical Descriptors
27
C162H233N47O38S1
3478.98
10.70
+3
-1.34
-0.926
Free
L
Linear
Free
Anticancer
S. pneumoniae
Evidence Records 7 records
Evidence 1 Activity

Activity

IC50
IC50= 50 µM
Anticancer
50 µM

Target

Leukemia Cancer
AML-2
Blood

Assay & Model

MTT/MTS assay
19.15-Min

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2005

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

IC50
IC50=51 µM
Anticancer
51 µM

Target

Leukemia Cancer
HL-60
Blood

Assay & Model

MTT/MTS assay
19.15-Min

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2005
Evidence 3 Activity

Activity

IC50
IC50= 46 µM
Anticancer
46 µM

Target

Blood Cancer
Jurkat
Blood

Assay & Model

MTT/MTS assay
19.15-Min

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2005
Evidence 4 Activity

Activity

IC50
IC50= 37 µM
Anticancer
37 µM

Target

Gastric Cancer
SNU-601
Stomach

Assay & Model

MTT/MTS assay
19.15-Min

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2005
Evidence 5 Activity

Activity

IC50
IC50= 29 µM
Anticancer
29 µM

Target

Breast Cancer
MCF-7
Breast

Assay & Model

MTT/MTS assay
19.15-Min

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2005
Evidence 6 Activity

Activity

0% Hemolysis
Toxicity
12.5 µM
Hemolytic Cytotoxic
0% Hemolysis | 12.5 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Functional and structural characteristics of anticancer peptide Pep27 analogues. | Cancer Cell Int | 2005
Evidence 7 Activity

Activity

% Hemolysis
Toxicity
0 %
Hemolytic Cytotoxic
Hemolytic_activity: Human RBCs(0% hemolysis at 0.19 µM, 0.39 µM, 0.78 µM, 1.56 µM, 3.12 µM, 6.25 µM, 12.5 µM) | Cytotoxicity: Not available

Target

erythrocytes

Source & Reference

NA
DRAMP
Cancer Cell Int. 2005 Jul 11 5:21.